# ArriVent BioPharma

Source: https://onco.cc/companies/arrivent/  
OnCo record `arrivent` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials.

## Summary

ArriVent BioPharma, based in Newtown Square, Pennsylvania and listed on Nasdaq since 2024, licenses medicines approved in China for development elsewhere. Its lead is furmonertinib (firmonertinib), a third-generation EGFR inhibitor from Allist Pharmaceuticals that is approved in China for EGFR-mutant non-small-cell lung cancer; ArriVent runs the global phase 3 FURVENT trial in EGFR exon 20 insertion mutations, where it holds FDA breakthrough designation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: ArriVent BioPharma, Inc.; ArriVent
- Tags: ctgov-sponsor
- HQ: Newtown Square, PA
- Type: biotech
- Website: https://www.arrivent.com

## Sources

- Official website: https://www.arrivent.com
- ClinicalTrials.gov: trials led by ArriVent BioPharma: https://clinicaltrials.gov/search?lead=ArriVent%20BioPharma

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)

---
JSON: https://onco.cc/api/v1/entities/arrivent.json